Concord Biotech Limited
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
What Concord files
- Others42
- Investor Meet42
- Important20
- Board Meeting13
- PPTs7
- Dividend/Bonus4
Concord Biotech faced a challenging FY26 with revenue down 12% to Rs 1,054.9 Cr and PAT falling 30% to Rs 259.2 Cr. This was primarily due to customer procurement delays, US tariff uncertainty, geopolitical disruptions, and a shift to staggered purchasing patterns. Despite this, the company strengthened operations by completing...
Concord Biotech's Q3FY26 revenue jumped 14% YoY to ₹278 Cr, driven by robust 24% growth in its API segment. However, 9MFY26 revenue saw a 5% dip to ₹729 Cr. Q3 PAT stood at ₹64 Cr (-16% YoY). EBITDA margins were 35.6%, impacted by new injectable facility commercialization and US subsidiary...
Concord Biotech reported Q2 FY26 revenue of Rs 247 Cr (down 20% YoY) and H1 FY26 revenue of Rs 451 Cr (down 14% YoY), with PAT at Rs 63 Cr and Rs 107 Cr respectively. This revenue dip was mainly due to temporary sales postponements from regulatory delays for EU...
Here's a summary of Concord Biotech's investor presentation: **Financial Highlights:** Q1FY26 revenue dipped 5% to 204 Cr, attributed to customer procurement lumpiness. EBITDA fell 24% to 61 Cr (30.1% margin) and PAT 26% to 44 Cr. Margins were impacted by new injectable facility expenses; adjusted EBITDA margin, however, was 37%....
1. Financial Highlights: Concord Biotech reported Q4 revenue of ₹429.9 Cr, up 35% YoY, and FY25 revenue of ₹1,200.1 Cr, up 18% YoY. EBITDA grew 42% in Q4 to ₹190.4 Cr (44.3% margin), with FY25 EBITDA at ₹506.3 Cr, up 17% (42.2% margin). PAT rose 48% in Q4 to ₹140.4...